Results
Title

Hypoalbuminemia is a surrogate biomarker of poor prognosis in myelodysplastic syndrome even when adjusting for comorbidities.

Authors

Sevindik, Omur Gokmen; Guc, Zeynep; Kahraman, Selda; Medeni Solmaz, Serife; Katgi, Abdullah; Acar, Celal; Alacacioglu, Inci; Piskin, Ozden; Ozsan, Guner Hayri; Demirkan, Fatih; Undar, Bulent; Ozcan, Mehmet Ali

Abstract

The serum albumin (SA) level has been reported to be an independent prognostic biomarker that may serve as a surrogate representative of disease biology in patients diagnosed with myelodysplastic syndrome (MDS). However, its prognostic ability has not been tested in a model adjusting for comorbidities. We analyzed 200 patients who were diagnosed as havingde novoMDS. Median overall survival (OS) of all patients was 25 months and median leukemia-free survival (LFS) was 24 months. Median OS according to the SA level groups of ≤ 3.5, 3.6–4.0 and > 4.0 mg/dL were 24, 39 and 77 months, respectively. SA level remained an independent predictor of both LFS and OS even when adjusting for the hematopoietic cell transplant comorbidity index (HCT-CI) and the International Prognostic Scoring System (IPSS) or World Health Organization classification-based Prognostic Scoring System (WPSS). Our findings indicate that SA level at the time of diagnosis is a significant and independent predictor of LFS and OS even when adjusting for commonly used prognostic systems and comorbidities.

Subjects

ALBUMINURIA; BIOMARKERS; MYELODYSPLASTIC syndromes; COMORBIDITY; LEUKEMIA

Publication

Leukemia & Lymphoma, 2015, Vol 56, Issue 9, p2552

ISSN

1042-8194

Publication type

Academic Journal

DOI

10.3109/10428194.2015.1014362